Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098513 · ClinicalTrials.gov registry record · Phase 1
GSK1349572 Relative Bioavailability Study
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01098513 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 24 participants.
The verdict
NCT01098513, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects. Part A will evaluate the relative bioavailability of two new tablet formulations compared to the current tablet formulation of GSK1349572 at 50 mg administered as single doses each comprising of two 25 mg tablets. Pharmacokinetic samples from Part A will be analyzed and, if at least one of the new formulations meets appropriate criteria and is selected, Part B will be a single-sequence design conducted to evaluate food effect of the selected new tablet formulation at one dose level. A subset of subjects enrolled in Part A will continue in Part B. Safety evaluations and serial PK samples will be collected during each treatment period. A follow-up visit will occur 7-28 days after the last dose of study drug.
Interventions
- DRUG GSK1349572 formulation AP
- DRUG GSK1349572 formulation AW
- DRUG GSK1349572 formulation AX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098513
The ClinicalTrials.gov registry entry for NCT01098513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GSK1349572 formulation AP is the first listed.
NCT01098513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01098513 about?
NCT01098513 is a clinical study titled "GSK1349572 Relative Bioavailability Study". This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects. Part A will evaluate the relative bioavailability of two new tablet formulations compared to the current tablet formulation of GSK1349572 at 50 mg administered as single doses each comprising of two...
What is the current status of trial NCT01098513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01098513?
The interventions under investigation include: GSK1349572 formulation AP (DRUG), GSK1349572 formulation AW (DRUG), GSK1349572 formulation AX (DRUG).
Who is sponsoring clinical trial NCT01098513?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.